Arbele BioTherapeutics Limited

ARBELE BIOTHERAPEUTICS LIMITED is a biopharmaceutical company focused on developing first-in-class antibody-based immunotherapeutic products to treat gastrointestinal (GI) cancers. The company's vision is to detect and defeat GI cancers, including stomach, pancreas, oesophagus, colon, liver and bile-duct cholangiocarcinoma, through breakthrough innovations. ARBELE specializes in immunotherapy and aims to provide first-in-class and best-in-class GI cancer drugs and premium diagnostic screening platforms. The company's lead asset, ARB202, is a humanized anti-CDH17xCD3 bispecific T-cell engager antibody. ARBELE has a strong presence in both the US and Hong Kong, and has been recognized with awards for innovation and entrepreneurship.